Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …

The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …

Introduction: Despite recent advances in pharmacological management, multiple sclerosis
(MS), an autoimmune disease of the central nervous system, remains a leading cause of …

Introduction: In the past decade, the role of B cells in the pathogenesis of multiple sclerosis
(MS) is coming to the forefront. Depletion of B cells by anti-CD20 monoclonal antibodies …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …

Multiple sclerosis (MS) therapy has evolved rapidly with an increased availability of several
immunomodulating therapies over the past two decades. Disease-modifying therapies have …

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …

Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible
for early disability in the young working population. In the last two decades, based on …